𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Acute effects on pulmonary haemodynamics of nifedipine in adult patients with cystic fibrosis

✍ Scribed by I. Eichler; O. C. Burghuber; M. Götz

Publisher
Springer
Year
1990
Tongue
English
Weight
214 KB
Volume
39
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis

Hypoxic pulmonary vasoconstriction is considered to be the primary cause of pulmonary hypertension and cor pulmonale in adult patients with cystic fibrosis (CF). The acute effect on pulmonary haemodynamics of a single sublingual dose of nifedipine 20 mg has been studied in 9 adult patients with CF. Nifedipine significantly attenuated the rise in mean pulmonary artery pressure and pulmonary vascular resistance induced by inhalation of a 13% oxygen gas mix. It also slightly reduced baseline pulmonary artery pressure and pulmonary vascular resistance and lowered pulmonary artery hypertension in the patients. Oxygen delivery was unchanged. Nifedipine is potentially useful for the treatment of hypoxic pulmonary hypertension in patients with CF.

📜 SIMILAR VOLUMES

Right ventricular performance and pulmon
Right ventricular performance and pulmonary haemodynamics in adolescent and adult patients with cystic fibrosis
✍ O. C. Burghuber; U. Salzer-Muhar; H. Bergmann; M. Götz 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 606 KB

A combined haemodynamic and radionuclide approach was used to evaluate right ventricular performance in 16 adolescent and adult patients with cystic fibrosis (CF). There were nine patients with mild arterial hypoxaemia (PaO2 greater than 80% of predicted) and normal resting pulmonary artery pressure

Evaluation of long term tobramycin thera
Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease
✍ U. Paporisz; H. G. Posselt; R. Wönne; W. Ristow; D. Röser; H. Knothe; S. W. Bend 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 493 KB

To nine cystic fibrosis patients with chronic bronchopulmonary infection of severely damaged lungs invaded by Pseudomonas aeruginosa, eleven courses of prolonged tobramycin treatment (5 mg/kg/day) for four to 16 weeks were administered. Pulmonary symptoms improved and a better quality of life was ac